Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials

Lancet

Volumn 358, Issue 9275, 2001, Pages 9-15

  Eikelboom, John W ^a   Quinlan, Daniel J ^b   Douketis, James D ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; NADROPARIN; PLACEBO; WARFARIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; GENETIC HETEROGENEITY; HUMAN; INFORMATION PROCESSING; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; META ANALYSIS; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; REDUCTION; RISK FACTOR; THROMBOEMBOLISM;

EID: 0035822248     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05249-1     Document Type: Article

References (35)

1. Prevention of venous thromboembolism
2. Evidence for the needs of out-of-hospital thrombosis prophylaxis: Introduction
3. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
4. Prolonged thromboprophylaxis following total hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
5. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
6. Ultrasonic screening before hospital discharge for deep vein thrombosis after arthroplasty: The post-arthroplasty screening study - A randomised controlled trial
7. The incidence of venographic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study in patients who underwent hip or knee arthroplasty
8. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial
9. Prevention of venous thromboembolism: International Consensus Statement - Guidelines compiled in accordance with the scientific evidence
10. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
11. Statistical aspects of the analysis of data from retrospective studies of disease
12. Bias in meta-analysis detected by a simple, graphical test
13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement
14. A double-blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery: The enoxaparin clinical trials group
15. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement
16. Efficacy and safety of post discharge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement: A prospective randomised double-blind placebo-controlled trial
17. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: The French study - Venographic outcome at 35 days
18. The post-hospital discharge venous thrombosis risk of the orthopedic patient
19. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: Enoxaparin
20. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: The Swedish study
21. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
22. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
23. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement
24. Venous thromboembolism after total hip arthroplasty: A review of incidence and prevention during hospitalization and after hospital discharge
25. Post-discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - An overview analysis
26. Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet
27. Summing up the evidence: One answer is not always enough
28. Why sources of heterogeneity in meta-analysis should be investigated
29. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty
30. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial
31. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism
32. Prolonged prophylaxis after joint replacement: Another step sideways?
33. Total hip replacements in the National Health Service: Is need being met?
34. Trends in the utilization of primary total hip arthroplasty, 1969 through 1990: A population-based study in Olmsted County, Minnesota